TelePrEP for HIV Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This study uses a rapid randomized controlled trial (RCT) design to examine HIV pre-exposure prophylaxis (PrEP) delivered through telehealth. This study will develop a knowledge base of small, effective changes to digital messaging and website design to improve telemedicine PrEP (telePrEP) provision for MISTR users in the United States.
Who Is on the Research Team?
Aaron Siegler, PhD
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
This trial is for people in the US who use MISTR, a telehealth service for HIV prevention (PrEP). Participants should be interested in starting or continuing PrEP through telemedicine. Specific inclusion and exclusion criteria are not detailed.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares different ways of delivering digital messages and website designs to improve how people start and stay on PrEP using telehealth. Participants are randomly assigned to receive standard care or new messaging approaches.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Individuals using MISTR services receiving an intervention condition.
Individuals using MISTR services receiving the standard of care.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.